Targeted Therapy Pralsetinib Achieves High Response Rates in Advanced Cancers: Study

In patients with RET fusion-positive thyroid cancers, pralsetinib achieved an overall response rate (ORR), said clinical trial results.

from Medindia Health News https://ift.tt/36OGtKT